Spotlight
Topics
DI Executive
Subscribe
- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SNMMI: Can Ultra-Low Dose PET Supplant the Need for CT Attenuation Correction?
Ultra-low dosing with long axial field-of-view positron emission tomography (PET) scanners facilitates qualitative PET imaging at a more than 50 percent reduction of conventional radiation dosing with PET, according to new research presented at the SNMMI 2024 conference.
The combination of long axial field-of-view (LAFOV) positron emission tomography (PET) scanners with a new ultra-low radiation dosing approach may offer a breakthrough in obtaining qualitative PET imaging without attenuation correction via computed tomography (CT), according to preliminary research findings presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Noting recent research looking at the use of Lutetium-176 background radiation from some PET scintillators as a transmission source, also referred to as LSO-TX, the study authors compared reconstructed PET images that utilized CT-derived attenuation maps and reconstructed PET images derived from LSO-TX.
The four study participants had 90-minute LAFOV PET scans as well as low-dose CT scans. The researchers said the LSO-TX attenuation maps, enhanced with deep learning, were based on a combination of reconstruction methods utilizing the maximum likelihoods for tomographic reconstruction (MLTR) and reconstruction of attenuation and activity (MLAA).
Here one can see reconstructed PET images (bottom row) and the use of CT- and LSO-TX-based attenuation maps (top row). Researchers said using ultra-low dose imaging with long axial field-of-view PET scanners obviates the need for accompanying computed tomography (CT) scans for attenuation correction. (Images courtesy of SNMMI.)
The researchers noted similar visualization between the CT- and LSO-TX attenuation mapping and the reconstructed PET images derived from both approaches. They found that CT attenuation correction resulted in 0.340 mSv dosing in contrast to 0.153 mSv dosing for LSO-TX.
“This reduction in radiation dose is 50 times lower than the standard PET dose and is comparable to the dose received from a mammogram or a chest CT radiograph,” explained lead study author Hasan Sari, Ph.D., a senior research scientist at Bern University Hospital in Bern and Siemens Healthineers International AG in Zürich, Switzerland.
The study authors noted the average relative change (RC) for the reconstructed PET images was – 3.2 for bones, -0.2 for water-based soft tissue and -1.8 for fat-based soft tissue. Average differences in standardized uptake value (SUV) included -3.0 for cerebral gray matter, 3.3 in the liver and – 4.5 in the descending aorta, according to the researchers.
“Ultra-low-dose protocols have the potential to extend the use of PET scans beyond their current applications and could significantly enhance the utility of this modality in screening studies involving at-risk or healthy subjects, research studies, enhanced treatment response assessments with more frequent follow-up scans, and pediatric scans,” emphasized Dr. Sari.
Reference
1. Sari H, Teimoorisichani M, Pyka T, et al. Ultra-low dose PET imaging in long axial field PET scanners with LSO transmission-based attenuation correction. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm . Accessed June 11, 2024.
Recent Videos
Related Content
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025Article
In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis
January 22nd 2025Article
Previously approved for the detection of neuritic beta amyloid plaque, the PET agent (18F)florbetaben is currently being evaluated in a phase 3 multicenter trial for the diagnosis of cardiac amyloidosis.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020Podcast
In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025Article
In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025Article
In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
